One shot vs. many: new drug may better protect young cancer patients from chemo side effects
NCT ID NCT06926751
First seen May 08, 2026 · Last updated May 20, 2026 · Updated 4 times
Summary
This study tests whether a single injection of Telpegfilgrastim works better than multiple daily injections of Filgrastim to prevent fever and dangerously low white blood cell counts caused by chemotherapy in children and teens (ages 6-24) with solid tumors. About 132 participants will receive one of the two drugs after each chemo cycle. The goal is to see which approach reduces infections, hospital stays, and treatment delays.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY-INDUCED NEUTROPENIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.